160 related articles for article (PubMed ID: 9616318)
1. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma.
Reubi JC; Waser B; Friess H; Büchler M; Laissue J
Gut; 1998 Apr; 42(4):546-50. PubMed ID: 9616318
[TBL] [Abstract][Full Text] [Related]
2. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma.
Masaki Y; Oka M; Ogura Y; Ueno T; Nishihara K; Tangoku A; Takahashi M; Yamamoto M; Irimura T
Hepatogastroenterology; 1999; 46(28):2240-5. PubMed ID: 10521973
[TBL] [Abstract][Full Text] [Related]
3. Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue.
Reubi JC; Waser B; Gugger M; Friess H; Kleeff J; Kayed H; Büchler MW; Laissue JA
Gastroenterology; 2003 Jul; 125(1):98-106. PubMed ID: 12851875
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.
Yin X; Wang M; Wang H; Deng H; He T; Tan Y; Zhu Z; Wu Z; Hu S; Li Z
Amino Acids; 2017 Aug; 49(8):1325-1335. PubMed ID: 28536844
[TBL] [Abstract][Full Text] [Related]
5. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located?
Reubi JC; Waser B; Schmassmann A; Laissue JA
Int J Cancer; 1999 May; 81(3):376-86. PubMed ID: 10209952
[TBL] [Abstract][Full Text] [Related]
6. Bombesin receptors in distinct tissue compartments of human pancreatic diseases.
Fleischmann A; Läderach U; Friess H; Buechler MW; Reubi JC
Lab Invest; 2000 Dec; 80(12):1807-17. PubMed ID: 11140694
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours.
Hessenius C; Bäder M; Meinhold H; Böhmig M; Faiss S; Reubi JC; Wiedenmann B
Eur J Nucl Med; 2000 Nov; 27(11):1684-93. PubMed ID: 11105825
[TBL] [Abstract][Full Text] [Related]
8. Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease.
Wang L; Friess H; Zhu Z; Graber H; Zimmermann A; Korc M; Reubi JC; Büchler MW
Clin Cancer Res; 2000 Feb; 6(2):566-71. PubMed ID: 10690540
[TBL] [Abstract][Full Text] [Related]
9. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
10. Blood-group sialyl-Tn antigen is more specific than Tn as a tumor marker in the pancreas.
Ching CK; Holmes SW; Holmes GK; Long RG
Pancreas; 1994 Nov; 9(6):698-702. PubMed ID: 7846011
[TBL] [Abstract][Full Text] [Related]
11. Evidence of
Marenco M; Lodola L; Persico MG; Frangipane V; Facoetti A; Aprile C; Hodolič M
Curr Pharm Biotechnol; 2018; 19(9):754-759. PubMed ID: 30160211
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin type 2A receptor immunoreactivity in human pancreatic adenocarcinomas.
Pilichowska M; Kimura N; Schindler M; Kobari M
Endocr Pathol; 2001; 12(2):147-55. PubMed ID: 11579680
[TBL] [Abstract][Full Text] [Related]
13. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.
Grützmann R; Lüttges J; Sipos B; Ammerpohl O; Dobrowolski F; Alldinger I; Kersting S; Ockert D; Koch R; Kalthoff H; Schackert HK; Saeger HD; Klöppel G; Pilarsky C
Br J Cancer; 2004 Mar; 90(5):1053-8. PubMed ID: 14997207
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1.
Wang JG; Li NN; Li HN; Cui L; Wang P
Neuropeptides; 2011 Apr; 45(2):151-6. PubMed ID: 21272935
[TBL] [Abstract][Full Text] [Related]
15. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
17. Regulatory peptide receptors in human hepatocellular carcinomas.
Reubi JC; Zimmermann A; Jonas S; Waser B; Neuhaus P; Läderach U; Wiedenmann B
Gut; 1999 Nov; 45(5):766-74. PubMed ID: 10517918
[TBL] [Abstract][Full Text] [Related]
18. Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia.
Körner M; Hayes GM; Rehmann R; Zimmermann A; Friess H; Miller LJ; Reubi JC
Am J Pathol; 2005 Oct; 167(4):959-68. PubMed ID: 16192632
[TBL] [Abstract][Full Text] [Related]
19. Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report.
Azuma T; Hirai M; Ito S; Yamamoto K; Taggart RT; Matsuba T; Yasukawa K; Uno K; Hayakumo T; Nakajima M
Int J Cancer; 1996 Aug; 67(4):492-7. PubMed ID: 8759606
[TBL] [Abstract][Full Text] [Related]
20. CAM 17.1--a new diagnostic marker in pancreatic cancer.
Gansauge F; Gansauge S; Parker N; Beger MI; Poch B; Link KH; Safi F; Beger HG
Br J Cancer; 1996 Dec; 74(12):1997-2002. PubMed ID: 8980403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
